Document is current
Any future updates will be listed below
-
Authors
Joly-Tonetti, Nicolas https://orcid.org/0009-0008-8491-6978
Legouffe, Raphael https://orcid.org/0000-0002-2421-1385
Tomezyk, Aurore
Gumez, Clémence
Gaudin, Mathieu https://orcid.org/0009-0002-1607-0313
Bonnel, David https://orcid.org/0009-0004-4159-261X
Schaller, Martin https://orcid.org/0000-0002-7930-1919
-
Funding
Funding for this research was provided by:
Galderma
- License Information
-
More Information
Article History
Received: 24 August 2023
Accepted: 12 April 2024
First Online: 7 May 2024
Declarations
:
: Nicolas Joly-Tonetti is an employee of Galderma SA, Lausanne, Switzerland. Clémence Gumez, Aurore Tomezyk, Raphael Legouffe, Mathieu Gaudin and David Bonnel are employees of Aliri (formerly ImaBiotech), Loos, France. Martin Schaller is an advisory board member for Galderma and Marpinion; a speaker for AbbVie, Bayer Healthcare, Galderma, and La Roche-Posay; a recipient of research grants from Galderma and Bayer HealthCare; and an investigator for GSK and Galderma.
: The samples used in these studies were sourced and deidentified via Tissue Solutions Ltd., a subsidiary of BioIVT LLC which is accredited for the collection, storage, and commercial distribution of biospecimens by the Office for Human Research Protections (OHRP) of the United States Department of Health. The use of publicly available biospecimens from an accredited supplier is not considered to fall under research in human subjects, and as such, IRB approval or exemption was not required.
